Michael J. Birrer, MD of Massachusetts General Hospital discusses toxicities of anti-PD-1 and anti-PD-L1 in gynecologic cancers at SGO 2016.
Transcription:
Database here is very limited said there’s been one study of about twenty patients an ovary. There’s been an adorable studies in cervix and endometrial cancer so we don’t have a big and. To look at toxicities it’s probably better to extrapolate. From the larger studies in lung cancer and melanoma and real cell in the bottom line is that he’s ageism extremely well tolerated. Yes skin rash is good za and some fifty. The biggest concern is auto immune phenomenon. And I think even there it’s not been anywhere near what people anticipated patients who have a history. Of auto immune phenomenon like all serve colitis should probably not go on these agents.